FIGURE 1.

Evaluation of the effects of intranodal cis‐dichlorodiammineplatinum(II) (CDDP) delivery into a tumor‐bearing lymph node (LN) by in vivo bioluminescence imaging. CDDP (2.0 mg/kg in saline) was delivered into the tumor‐bearing subiliac LN (SiLN) on days 1 and 4 (KM‐Luc/GFP; A, B) or day 3 (FM3A‐Luc; C, D). Tumor proliferation was evaluated from measurements of luciferase activity, which was normalized to the value on day 1 (KM‐Luc/GFP) or day 3 (FM3A‐Luc). A, In vivo bioluminescence imaging of SiLN inoculated with KM‐Luc/GFP cells. A solution of CDDP (n = 13) or saline (control, n = 14) was injected into the tumor‐bearing SiLN on days 1 and 4 after tumor inoculation. B, Luciferase activity rapidly increased in the control group, but this elevation was suppressed by treatment with CDDP. C, In vivo bioluminescence imaging of SiLN inoculated with FM3A‐Luc cells. A solution of CDDP (n = 11) or saline (control, n = 12) was injected into the tumor‐bearing SiLN on day 3 after tumor inoculation. D, Although luciferase activity exhibited a progressive increase in the control group (FM3A‐Luc + saline), it exhibited a continuous decrease between day 5 and day 14 in the group treated with only a single dose of CDDP (FM3A‐Luc + CDDP). Error bars represent SEM. **P < .01